Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial

Gratzke C.J.; Egils Vjaters; Fizazi K.; C.J. GratzkeK. FizaziNeal Shore[...]F. Verholen; Verholen; Shore N.D.; Smith M.R.; C.J. GratzkeK. FizaziNeal Shore[...]F.; Feyerabend S.; Grabbert M.; Carles J.; Lebret T.

doi:10.1016/j.annonc.2021.08.1143

Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial

Gratzke C.J.
, Egils Vjaters
, Fizazi K.
, C.J. GratzkeK. FizaziNeal Shore[...]F. Verholen
, Verholen
, Shore N.D.
, Smith M.R.
, C.J. GratzkeK. FizaziNeal Shore[...]F.
, Feyerabend S.
, Grabbert M.
, Carles J.
, Lebret T.

Ne LU

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Journal	Annals of Oncology
Volume	32
DOIs	https://doi.org/10.1016/j.annonc.2021.08.1143
Publication status	Published - 2021

OECD Field of Science

3. Medical and Health Sciences

Access to Document

10.1016/j.annonc.2021.08.1143

Cite this

C.J., G., Vjaters, E., K., F., GratzkeK. FizaziNeal Shore[...]F. Verholen, C. J., Verholen, N.D., S., M.R., S., C.J. GratzkeK. FizaziNeal Shore[...]F., S., F., M., G., J., C., & T., L. (2021). Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial. Annals of Oncology, 32. https://doi.org/10.1016/j.annonc.2021.08.1143

@article{24589166680f4110b7d55dedfd22494e,

title = "Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial",

author = "Gratzke C.J. and Egils Vjaters and Fizazi K. and \{GratzkeK. FizaziNeal Shore[...]F. Verholen\}, C.J. and Verholen and Shore N.D. and Smith M.R. and \{C.J. GratzkeK. FizaziNeal Shore[...]F.\} and Feyerabend S. and Grabbert M. and Carles J. and Lebret T.",

year = "2021",

doi = "10.1016/j.annonc.2021.08.1143",

language = "English",

volume = "32",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

}

C.J., G, Vjaters, E, K., F, GratzkeK. FizaziNeal Shore[...]F. Verholen, CJ, Verholen, N.D., S, M.R., S, C.J. GratzkeK. FizaziNeal Shore[...]F., S., F, M., G, J., C & T., L 2021, 'Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial', Annals of Oncology, vol. 32. https://doi.org/10.1016/j.annonc.2021.08.1143

TY - JOUR

T1 - Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial

AU - C.J., Gratzke

AU - Vjaters, Egils

AU - K., Fizazi

AU - GratzkeK. FizaziNeal Shore[...]F. Verholen, C.J.

AU - Verholen, null

AU - N.D., Shore

AU - M.R., Smith

AU - C.J. GratzkeK. FizaziNeal Shore[...]F., null

AU - S., Feyerabend

AU - M., Grabbert

AU - J., Carles

AU - T., Lebret

PY - 2021

Y1 - 2021

UR - https://www.annalsofoncology.org/article/S0923-7534(21)03372-X/fulltext#relatedArticles

U2 - 10.1016/j.annonc.2021.08.1143

DO - 10.1016/j.annonc.2021.08.1143

M3 - Meeting abstract

SN - 0923-7534

VL - 32

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial

OECD Field of Science

Access to Document

Other files and links

Cite this